Aptose Tuspetinib Data Featured in Oral Presentation
Dr. Naval Daver from MD Anderson Cancer Center will present data from Aptose™s AML Drug Candidate Tuspetinib in an Oral Presentation at ASH 2023
Aptose Presents Latest Available Data on AML Drug Tuspetinib - 48% ORR with TUS/VEN in Heavily Pre-treated R/R AML Patients
Aptose to Hold Clinical Update Webcast and KOL Data Review of AML Drug Tuspetinib on Monday, October 30th